NASDAQ:ATYR aTyr Pharma Q3 2026 Earnings Date & Estimates $0.18 +0.00 (+0.27%) Closing price 04:00 PM EasternExtended Trading$0.19 +0.01 (+2.83%) As of 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. aTyr Pharma is estimated to report Q3 2026 earnings on Thursday, November 5, 2026, before market opens. The conference call is scheduled for November 6, 2026 at 4:00 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 5, 2026TimeBefore Market OpensConference Call DateNovember 6, 2026Conference Call4:00 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from aTyr Pharma in Q3 2026aTyr Pharma is expected to post earnings of -$0.11 per share on revenue of $2.50 million. In the same quarter a year earlier aTyr Pharma reported -$0.26 per share on revenue of $0.19 million. aTyr Pharma last reported on August 7, 2026, posting -$0.11 per share and beating the -$0.1214 consensus estimate. aTyr Pharma has beaten the consensus EPS estimate in 5 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.11Expected Revenue$2.50 millionPrior-Year EPS-$0.26Prior-Year Revenue$0.19 millionExpected Revenue Growth+1,215.8%Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.11 (Beat by +$0.0114)EPS Beat Rate5 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report aTyr Pharma Q3 2026 Earnings FAQ When does aTyr Pharma report Q3 2026 earnings? aTyr Pharma (NASDAQ:ATYR) is estimated to report Q3 2026 earnings on Thursday, November 5, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it. What time is aTyr Pharma's Q3 2026 earnings call? aTyr Pharma's Q3 2026 earnings conference call is scheduled for Friday, November 6, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for aTyr Pharma? Analysts expect aTyr Pharma to post earnings of -$0.11 per share for Q3 2026. How much revenue is aTyr Pharma expected to report? The consensus revenue estimate for aTyr Pharma is $2.50 million for Q3 2026. aTyr Pharma Earnings HeadlinesATyr Pharma, Inc. Announces Publication Demonstrating Anti-Fibrotic Effects Of ATYR0101 In The Journal Of Biological ChemistryOctober 13 at 8:08 PM | marketscreener.comMATyr Pharma, Inc. Announces Publication Demonstrating Anti-Fibrotic Effects Of ATYR0101 In The Journal Of Biological ChemistryOctober 13 at 8:08 PM | marketscreener.comMIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially the reasons why we’re bombing the country.October 15 at 1:00 AM | Banyan Hill Publishing (Ad)aTyr Pharma Announces Publication Demonstrating Anti-Fibrotic Effects of ATYR0101 in the Journal of Biological ChemistryOctober 13 at 8:00 AM | globenewswire.comaTyr Pharma (NASDAQ:ATYR) Shares Down 2.3% - Here's What HappenedOctober 7, 2026 | americanbankingnews.comPositive FDA Alignment Boosts ATyr Pharma's Rare Lung DiseaseSeptember 24, 2026 | benzinga.comSee More aTyr Pharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like aTyr Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on aTyr Pharma and other key companies, straight to your email. Email Address About aTyr PharmaaTyr Pharma (NASDAQ:ATYR) (NASDAQ: ATYR) is a biotechnology company focused on developing medicines that regulate immune responses and treat serious diseases. The company’s research is based on the therapeutic potential of extracellular functions of tRNA synthetases, a group of proteins traditionally known for their role in protein production but increasingly studied for their involvement in inflammation, tissue repair and immune regulation. aTyr’s lead product candidate is efzofitimod, an engineered protein based on histidyl-tRNA synthetase. It is designed to modulate immune activity through neuropilin-2 and has been developed primarily for pulmonary sarcoidosis, a rare inflammatory lung disease. The company has also investigated efzofitimod in other inflammatory and fibrotic conditions, while evaluating additional product candidates aimed at diseases involving immune-system dysfunction. Founded in 2005 and headquartered in San Diego, California, aTyr conducts its research and clinical development activities in collaboration with medical institutions, research organizations and industry partners. The company’s leadership includes Sanjay S. Shukla, M.D., who serves as president and chief executive officer. aTyr’s programs have received regulatory recognition, including orphan-drug and Breakthrough Therapy designations for efzofitimod in pulmonary sarcoidosis.View aTyr Pharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Apple Cut iPhone 18 Orders; What Does It Mean For Suppliers?Domino’s Pizza: As Cheap As It Gets, Nowhere to Go But UpFastenal Flashes Bullish Signal as Uptrend Holds Despite Margin PressureASML Can’t Keep Up With AI Demand—Why That's a Good ThingCiti Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenBig Banks Report Strong Earnings—So Why Are Shares Falling? Upcoming Earnings Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
